Since its debut in 1996, the ISMRC has established itself, every other year, as a premier event showcasting the detection, characterization & clinical relevance of Circulating Tumor Cells (CTC) in solid tumors in association with companies, experts in CTCs, developing technologies as well as drug discovery enterprises. The PARIS - ISMRC 2013 program will feature compelling oral communication from industry and academia on new trends in the CTC field: Metastasis biology, Novel CTC assays, CTC Clinical relevance (breast, prostate, colon, lung, bladder, head & neck, gastro-intestinal tract cancers, melanoma...) including their molecular characteristics. The PARIS - ISMRC 2013 continues to propose oral communications and poster presentations on CTCs with a new track for 2013: The interest in other cell-free circulating markers (i.e., tumor cell-free DNA & microRNA).

We invite you to submit your abstract for consideration by our Advisory Committee for presentation at the 9th Annual International Symposium of Minimal Residual Cancer (ISMRC). After great cities like Munich, Berlin, Oslo, San-Francisco, Hamburg, Athens & Osaka, the next ISMRC will take place September 25-27, 2013 at the Pullman Bercy in Paris, France.

Many experts in this field all over the world already accepted to participate & share their viewpoint on this very hot topic in Cancer Research.

Spanning four days, the PARIS - ISMRC 2013 meeting includes a full-time plenary session with one mini-session including 3 parallel tracks on CTC & clinical studies and propose one pre-conference day at Institut Curie. It will be a great opportunity to exchange all the new data.